Brief: Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal
05/03/2026 12:03
March 5 (Reuters) - BioXcel Therapeutics Inc BTAI.O: BIOXCEL THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 TOPLINE RESULTS FROM COLUMBIA UNIVERSITY-LED STUDY OF BXCL501 FOR TREATMENT OF OPIOID WITHDRAWAL BIOXCEL THERAPEUTICS INC: BXCL501 DEMONSTRATED CLINICAL BENEFITS AND FAVORABLE TOLERABILITY PROFILE FOR TREATMENT OF OPIOID WITHDRAWAL SYMPTOMS Source text: ID:nGNX4yKQqN Further company coverage: BTAI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty